Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.

@article{Giesinger2016ReplicationAV,
  title={Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.},
  author={Johannes M. Giesinger and Jacobien M Kieffer and Peter M. Fayers and Mogens Groenvold and Morten Petersen and Neil W. J. Scott and Mirjam A Sprangers and Galina Velikova and Neil K Aaronson},
  journal={Journal of clinical epidemiology},
  year={2016},
  volume={69},
  pages={
          79-88
        }
}
OBJECTIVE To further evaluate the higher order measurement structure of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), with the aim of generating a summary score. STUDY DESIGN AND SETTING Using pretreatment QLQ-C30 data (N = 3,282), we conducted confirmatory factor analyses to test seven previously evaluated higher order models. We compared the summary score(s) derived from the best performing higher order model with the… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 46 CITATIONS

Anxiety and depression in patients with haematological neoplasms in Malaysia.

  • The Medical journal of Malaysia
  • 2019
VIEW 1 EXCERPT
CITES METHODS

Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out

Imogen Ramsey, Belle H. de Rooij, +4 authors Lonneke V. van de Poll-Franse
  • Journal of Cancer Survivorship
  • 2019
VIEW 1 EXCERPT
CITES METHODS

Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2019
VIEW 1 EXCERPT
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).

  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2013
VIEW 1 EXCERPT

treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3 , randomized , controlled , BOLERO - 2 trial

T Raykov
  • 2013